BridgeBio Oncology Therapeutics: president and CEO Pedro Beltran sold 1,047 shares

What happened The Form 4 filed Oct 05, 2026, reports that Pedro Beltran, president and CEO and director, had 1,047 shares withheld by the issuer to satisfy tax withholding at $3.94 per share, totaling $4,125, on Oct 01, 2026.

Key details

• Transaction date and price: Oct 01, 2026; $3.94 per share; total $4,125.
• Transaction code: F (payment of exercise price or tax liability); disposition: withheld/disposed.
• Shares owned after the transaction: not reported in the filing.
• Footnote F1: the shares were withheld by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
• Filing date: Oct 05, 2026.

Why it may matter

• The filing shows this was a tax withholding related to RSU vesting rather than an open-market sale. A filing does not show why the insider traded or why the company acted.